

## Pharmacotherapeutic report on silodosin (Silodyx®) for the treatment of Lower Urinary Tract Symptoms (LUTS)

**Medicine. silodosin, capsule 4 mg, 8 mg.**

### **Summary of the therapeutic value**

**Intended effects.** Silodosin was shown to be non-inferior to tamsulosin in a short-term clinical trial. An indirect comparison between silodosin and alfuzosin, doxazosin and terazosin showed that the effect of silodosin on the international prostate symptom score (IPSS), quality of life (QOL) score and maximum urine flow rate (Qmax) was comparable with the effects of the other alpha-1 adrenergic blockers.

**Unintended effects.** The differences in unintended effects of silodosin seemed small when compared with the other alpha-1 adrenergic blockers.

**Experience.** Limited experience has been gained with silodosin and considerable experience with the other alpha-1 adrenergic blockers.

**Applicability.** In general, silodosin and the other alpha-1 adrenergic blockers are similar with regards to: contraindications, interactions with other medicinal products, and special warnings and precautions for use.

**Ease of use.** There seems to be no clinically important difference with regards to the dose frequency or the method of administration between silodosin and the other alpha-1 adrenergic blockers.

**Final conclusion.** The intended and unintended effects of silodosin are comparable with the effects of tamsulosin, alfuzosin, doxazosin and terazosin. In addition, there are no clinically important differences in the applicability or ease of use between these agents.

For the treatment of patients with LUTS, the therapeutic value of silodosin is comparable with that of tamsulosin, alfuzosin, doxazosin and terazosin.